🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07352293
Active, not recruiting Phase 4

The Value of Methotrexate in NCES for Stable Vitiligo

NCT07352293 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 4
Started
2026-03-03
Last updated
2026-06-08

Condition(s) studied

Vitiligo

Investigational drug(s) / intervention(s)

Non cultured epidermal suspension

Non cultured epidermal suspension: Under aseptic precautions and local anesthesia, a Thiersch graft about one-third the size of the recipient area will be harvested from the donor site (usually upper thigh/ buttocks). The skin graft will be transferred to trypsin-EDTA solution and incubated at 37 °C for 20-30 minutes to separate epidermis from the dermis and then washed with PBS. The tissue will be teased gently with sterile forceps to release epidermal cells from the trypsin digested graft. The white dermis will be removed, and the suspension will be centrifuged at 1000g for 5-10 minutes and the supernatant will be discarded. Under strict asepsis, the recipient vitiliginous areas will be anesthetized followed by fractional laser CO2 resurfacing, using dot mode off resurfacing at a power of 18-20 W, dwell time 1,500-2000 milliseconds (DEKA, Florence, Italy). One to three passes will be performed until the epidermis is removed uniformly. Then, the NCES will be applied and uniformly spread.

Study summary

The goal of this clinical trial is to learn if adding a six months course of Methotrexate would improve the results of non cultured epidermal suspension (NCES) in adult patients with acral and resistant vitiligo lesions over the elbows and knees. researchers will compare results of NCES in two groups one group will receive Methotrexate for 3 months prior to the procedure and 3 months after the procedure, while the other group will not receive the drug. Patients will receive PUVA hand \& feet 3 times/week for 3 months after NCES during this period they will be followed up monthly to evaluate repigmentation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
* Inclusion criteria: * Patients with non-segmental vitiligo (NSV) with acral or resistant lesions over the elbows and knees, that has not responded to conventional treatment * Stability for ≥ 1 year * Age ≥18 years * Exclusion criteria: * Segmental vitiligo * Active vitiligo; new lesions, expansion of old lesions, confetti like lesions, ill-defined edges or koebnerization in \< 1 year * Age \< 18 years. * Pregnant females. * Patients with hematologic, hepatic, renal disease or chronic infection. * Topical treatment in the past month and systemic treatment in the past 3 months.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Dermatology Outpatient Clinic, Kasr al Ainy Teaching Hospital, Cairo University Cairo Egypt

More Cairo University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07352293 on ClinicalTrials.gov ↗ ← All trials in Egypt